Glaucoma misconceptions common among patients

Article

Patients with established glaucoma have only slightly greater knowledge of their condition than patients who are newly diagnosed.

Patients with established glaucoma have only slightly greater knowledge of their condition than patients who are newly diagnosed, according to a report published in the January/February issue of Clinical & Experimental Ophthalmology.

Helen Danesh-Meyer and colleagues from Greenelane Clinical Centre, Auckland, the Southern Eye Specialists, Christchurch and the University of Auckland, New Zealand recruited 208 glaucoma patients, 100 newly diagnosed glaucoma patients and 100 controls. Each subject completed a validated self-administered true/false questionnaire assessing glaucoma knowledge.

Established glaucoma patients had marginally but significantly (p<0.05) greater glaucoma knowledge scores than new patients. Both groups scored significantly better than the control population. Significant misconceptions regarding glaucoma include: 80% of all participants thought that topical medications could not have systemic side-effects and 48% of established glaucoma patients believed that symptoms would warn them of disease progression. One-third of new patients considered blindness to be a common outcome of glaucoma.

Glaucoma patients are likely to harbour significant misconceptions about the disease. As such, the authors of this report believe that educational materials should be tailored to address this issue.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.